An amylin analog used as a challenge test for Alzheimer's disease

Haihao Zhu, Robert A. Stern, Qiushan Tao, Alexandra Bourlas, Maritza D. Essis, Meenakshi Chivukula, James Rosenzweig, Devin Steenkamp, Weiming Xia, Gustavo A. Mercier, Yorghos Tripodis, Martin Farlow, Neil Kowall, Wei Qiao Qiu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction Preclinical studies demonstrate the potential of amylin in the diagnosis of Alzheimer's disease (AD). We aimed to lay the foundation for repurposing the amylin analog and a diabetes drug, pramlintide, for AD in humans. Methods We administered a single subcutaneous injection of 60 μg of pramlintide to nondiabetic subjects under fasting conditions. Results None of the participants developed hypoglycemia after the injection of pramlintide. The pramlintide challenge induced a significant surge of amyloid-β peptide and a decrease in total tau in the plasma of AD subjects but not in control participants. The pramlintide injection provoked an increase in interleukin 1 receptor antagonist and a decrease in retinol-binding protein 4, which separates AD subjects from control subjects. Discussion Pramlintide use appeared to be safe in the absence of diabetes. The biomarker changes as a result of the pramlintide challenge, which distinguished AD from control subjects and mild cognitive impairment.

Original languageEnglish (US)
Pages (from-to)33-43
Number of pages11
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Islet Amyloid Polypeptide
Alzheimer Disease
Retinol-Binding Proteins
Injections
Interleukin-1 Receptors
Subcutaneous Injections
pramlintide
Hypoglycemia
Amyloid
Fasting
Biomarkers
Peptides

Keywords

  • Alzheimer's disease (AD)
  • Amylin challenge
  • Biomarkers
  • Diagnosis
  • Pramlintide
  • Safety

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

An amylin analog used as a challenge test for Alzheimer's disease. / Zhu, Haihao; Stern, Robert A.; Tao, Qiushan; Bourlas, Alexandra; Essis, Maritza D.; Chivukula, Meenakshi; Rosenzweig, James; Steenkamp, Devin; Xia, Weiming; Mercier, Gustavo A.; Tripodis, Yorghos; Farlow, Martin; Kowall, Neil; Qiu, Wei Qiao.

In: Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 3, No. 1, 01.01.2017, p. 33-43.

Research output: Contribution to journalArticle

Zhu, H, Stern, RA, Tao, Q, Bourlas, A, Essis, MD, Chivukula, M, Rosenzweig, J, Steenkamp, D, Xia, W, Mercier, GA, Tripodis, Y, Farlow, M, Kowall, N & Qiu, WQ 2017, 'An amylin analog used as a challenge test for Alzheimer's disease', Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 3, no. 1, pp. 33-43. https://doi.org/10.1016/j.trci.2016.12.002
Zhu, Haihao ; Stern, Robert A. ; Tao, Qiushan ; Bourlas, Alexandra ; Essis, Maritza D. ; Chivukula, Meenakshi ; Rosenzweig, James ; Steenkamp, Devin ; Xia, Weiming ; Mercier, Gustavo A. ; Tripodis, Yorghos ; Farlow, Martin ; Kowall, Neil ; Qiu, Wei Qiao. / An amylin analog used as a challenge test for Alzheimer's disease. In: Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2017 ; Vol. 3, No. 1. pp. 33-43.
@article{a3ce58a49c6146958d6d38924f665e17,
title = "An amylin analog used as a challenge test for Alzheimer's disease",
abstract = "Introduction Preclinical studies demonstrate the potential of amylin in the diagnosis of Alzheimer's disease (AD). We aimed to lay the foundation for repurposing the amylin analog and a diabetes drug, pramlintide, for AD in humans. Methods We administered a single subcutaneous injection of 60 μg of pramlintide to nondiabetic subjects under fasting conditions. Results None of the participants developed hypoglycemia after the injection of pramlintide. The pramlintide challenge induced a significant surge of amyloid-β peptide and a decrease in total tau in the plasma of AD subjects but not in control participants. The pramlintide injection provoked an increase in interleukin 1 receptor antagonist and a decrease in retinol-binding protein 4, which separates AD subjects from control subjects. Discussion Pramlintide use appeared to be safe in the absence of diabetes. The biomarker changes as a result of the pramlintide challenge, which distinguished AD from control subjects and mild cognitive impairment.",
keywords = "Alzheimer's disease (AD), Amylin challenge, Biomarkers, Diagnosis, Pramlintide, Safety",
author = "Haihao Zhu and Stern, {Robert A.} and Qiushan Tao and Alexandra Bourlas and Essis, {Maritza D.} and Meenakshi Chivukula and James Rosenzweig and Devin Steenkamp and Weiming Xia and Mercier, {Gustavo A.} and Yorghos Tripodis and Martin Farlow and Neil Kowall and Qiu, {Wei Qiao}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.trci.2016.12.002",
language = "English (US)",
volume = "3",
pages = "33--43",
journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",
issn = "2352-8737",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - An amylin analog used as a challenge test for Alzheimer's disease

AU - Zhu, Haihao

AU - Stern, Robert A.

AU - Tao, Qiushan

AU - Bourlas, Alexandra

AU - Essis, Maritza D.

AU - Chivukula, Meenakshi

AU - Rosenzweig, James

AU - Steenkamp, Devin

AU - Xia, Weiming

AU - Mercier, Gustavo A.

AU - Tripodis, Yorghos

AU - Farlow, Martin

AU - Kowall, Neil

AU - Qiu, Wei Qiao

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction Preclinical studies demonstrate the potential of amylin in the diagnosis of Alzheimer's disease (AD). We aimed to lay the foundation for repurposing the amylin analog and a diabetes drug, pramlintide, for AD in humans. Methods We administered a single subcutaneous injection of 60 μg of pramlintide to nondiabetic subjects under fasting conditions. Results None of the participants developed hypoglycemia after the injection of pramlintide. The pramlintide challenge induced a significant surge of amyloid-β peptide and a decrease in total tau in the plasma of AD subjects but not in control participants. The pramlintide injection provoked an increase in interleukin 1 receptor antagonist and a decrease in retinol-binding protein 4, which separates AD subjects from control subjects. Discussion Pramlintide use appeared to be safe in the absence of diabetes. The biomarker changes as a result of the pramlintide challenge, which distinguished AD from control subjects and mild cognitive impairment.

AB - Introduction Preclinical studies demonstrate the potential of amylin in the diagnosis of Alzheimer's disease (AD). We aimed to lay the foundation for repurposing the amylin analog and a diabetes drug, pramlintide, for AD in humans. Methods We administered a single subcutaneous injection of 60 μg of pramlintide to nondiabetic subjects under fasting conditions. Results None of the participants developed hypoglycemia after the injection of pramlintide. The pramlintide challenge induced a significant surge of amyloid-β peptide and a decrease in total tau in the plasma of AD subjects but not in control participants. The pramlintide injection provoked an increase in interleukin 1 receptor antagonist and a decrease in retinol-binding protein 4, which separates AD subjects from control subjects. Discussion Pramlintide use appeared to be safe in the absence of diabetes. The biomarker changes as a result of the pramlintide challenge, which distinguished AD from control subjects and mild cognitive impairment.

KW - Alzheimer's disease (AD)

KW - Amylin challenge

KW - Biomarkers

KW - Diagnosis

KW - Pramlintide

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85012247300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012247300&partnerID=8YFLogxK

U2 - 10.1016/j.trci.2016.12.002

DO - 10.1016/j.trci.2016.12.002

M3 - Article

VL - 3

SP - 33

EP - 43

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

SN - 2352-8737

IS - 1

ER -